pantothenic acid has been researched along with HIV Coinfection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chapman, R; Douglass, N; Garcia, I; Jacobs, W; Ryffel, B; Sambandamurthy, V; Shephard, E; Stutz, H; Williamson, AL | 1 |
| Chen, B; Derrick, SC; Jacobs, WR; Jalapathy, KV; Morris, SL; Russell, RG; Sambandamurthy, VK | 1 |
2 other study(ies) available for pantothenic acid and HIV Coinfection
| Article | Year |
|---|---|
Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
Topics: AIDS Vaccines; Animals; BCG Vaccine; CD8-Positive T-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Gene Products, gag; HIV Infections; HIV-1; Immunization, Secondary; Interferon-gamma; Interleukin-6; Mice; Mice, Inbred BALB C; Mice, SCID; Mycobacterium bovis; Pantothenic Acid; Spleen; Tumor Necrosis Factor-alpha; Vaccination; Vaccinia virus | 2012 |
Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.
Topics: Animals; HIV Infections; Humans; Lysine; Mice; Mycobacterium tuberculosis; Pantothenic Acid; Time Factors; Tuberculosis; Tuberculosis Vaccines; Vaccines, Attenuated | 2005 |